Resources

Selected
  • Systematic reviews (SYSVAC)
Type of publications
Regions
Diseases
Vaccine topics
Target population
Publication date

3220 results found

2024 ∙ Bytyci, J. Ying, Y. Lee, L. Y. W.

Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: A systematic review

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Tian, Z. Chen, Y. Yao, Y. Chen, L. Zhu, X. Shen, Z. Yang, S. Jin, H.

Immunogenicity and risk factors for poor humoral immune response to SARS-CoV-2 vaccine in patients with autoimmune hepatitis: a systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Rosso, A. Flacco, M. E. Cioni, G. Tiseo, M. Imperiali, G. Bianconi, A. Fiore, M. Calo, G. L. Orazi, V. Troia, A. Manzoli, L.

Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis

  • Adults
  • Adolescents
  • Older adults
  • Chikungunya
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Yin, J. Zhang, L. Wang, C. Qin, C. Miao, M.

Immunogenicity and safety of ebolavirus vaccines in healthy adults: a systematic review and meta-analysis of randomized controlled trials

  • Adults
  • Ebola
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Carta, V. Mangeri, L. Tiecco, G. Foca, E. Quiros-Roldan, E. De Francesco, M. A.

Immunogenicity and safety of live attenuated and recombinant/inactivated varicella zoster vaccines in people living with HIV: A systematic review

  • Children
  • Adolescents
  • Adults
  • Varicella
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Wagner, G. Gartlehner, G. Thaler, K. Ledinger, D. Feyertag, J. Klerings, I. Saif-Ur-Rahman, K. M. Devane, D. Olsson, K. Adel Ali, K. Vygen-Bonnet, S. Salo, H. Zavadska, D. Grgic Vitek, M. Oona, M. Cunney, R. Tuerlinckx, D. Kristensen Lomholt, F. Sommer, I.

Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis

  • All age groups
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Moderate
2024 ∙ Domnich, A. Trombetta, C. S. Fallani, E. Salvatore, M.

Immunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis

  • Adults
  • Influenza
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
High
2024 ∙ Ma, B. M. Tam, A. R. Chan, K. W. Hung, I. F. N. Tang, S. C. W. Chan, T. M. Yap, D. Y.

Immunogenicity and Safety of the Three-Dose COVID-19 Vaccine Regimen in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Low
2024 ∙ Feng, S. McLellan, J. Pidduck, N. Roberts, N. Higgins, J. P. Choi, Y. Izu, A. Jit, M. Madhi, S. A. Mulholland, K. Pollard, A. J. Procter, S. Temple, B. Voysey, M.

Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis

  • Newborn
  • Children
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Ouyang, L. Lei, G. Gong, Y.

Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
Loading...